Literature DB >> 3381752

Usefulness of a rapid initial increase in plasma creatine kinase activity as a marker of reperfusion during thrombolytic therapy for acute myocardial infarction.

B S Lewis1, W Ganz, P Laramee, B Cercek, H Hod, P K Shah, A S Lew.   

Abstract

This study evaluates a new nonangiographic marker of reperfusion--a rapid initial increase in plasma creatine kinase (CK) and CK-MB activity--in 50 patients receiving intracoronary streptokinase. Blood for CK and CK-MB activity was sampled at 30-minute intervals and angiography performed at 15-minute intervals or earlier if there were clinical signs suggestive of reperfusion. An absolute first-hour increase in CK activity of 480 +/- 345 IU/liter (range 54 to 1,440 IU/liter), or a relative first-hour increase of 34 +/- 18% (range 13 to 67% of the peak rise), or an absolute first-hour increase in CK-MB activity of 48 +/- 36 IU/liter (range 10 to 144 IU/liter) or a relative first-hour increase of 27 +/- 13% (range 13 to 57%) was found in patients immediately after reperfusion with Thrombolysis In Myocardial Infarction (TIMI) grade 3 perfusion of the artery of infarction. The onset of rapid increase in CK and CK-MB activity closely reflected the time of angiographic documentation of reperfusion. In contrast, in the absence of reperfusion, the absolute rate of increase in CK activity measured in the last hour of the 2 1/2-hour period beginning with the start of treatment was only 15 +/- 9 IU/liter on the average (range 2 to 30 IU/liter) and the relative rate of rise was 3 +/- 2% on the average (range 1 to 6%).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3381752     DOI: 10.1016/0002-9149(88)91358-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  16 in total

1.  ECG monitoring, biochemical Testing, and Anticoagulation Assessment.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 2.  Cardiology.

Authors:  L D Smith; D J Coltart
Journal:  Postgrad Med J       Date:  1990-04       Impact factor: 2.401

3.  French multicenter trial of anistreplase versus heparin in acute myocardial infarction.

Authors:  H Lardoux; Y Louvard; D de Vernejoul; C Picot; M Baudet; M Hiltgen; M Houplon; J Ponsonnaille; M Richard; R Luccioni
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

Review 4.  Exercise training as therapy for chronic heart failure.

Authors:  N G Uren; D P Lipkin
Journal:  Br Heart J       Date:  1992-06

5.  Evaluation of coronary artery patency using cardiac markers.

Authors:  Milenko J Tanasijevic
Journal:  J Thromb Thrombolysis       Date:  2005-02       Impact factor: 2.300

6.  Non-invasive diagnosis of infarct artery patency after acute myocardial infarction by use of serial plasma troponin T concentrations: importance of measurement of peak levels.

Authors:  R M Norris; R N Johnson; H D White; D R Robinson
Journal:  Heart       Date:  1996-05       Impact factor: 5.994

Review 7.  [Enzymatic markers of reperfusion in acute myocardial infarct. With data from the ISAM study].

Authors:  S Walter; J Carlsson; R Schröder; K L Neuhaus; E Sorges; U Tebbe
Journal:  Herz       Date:  1999-10       Impact factor: 1.443

8.  Protection of islet cells from inflammatory cell death in vitro.

Authors:  V Burkart; H Kolb
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

9.  Are enzymatic tests good indicators of coronary reperfusion?

Authors:  H A Bosker; A van der Laarse; V M Cats; A V Bruschke
Journal:  Br Heart J       Date:  1992-02

10.  Efficacy and safety of a new streptokinase regimen with enoxaparin in acute myocardial infarction.

Authors:  Gabriel Tatu-Chitoiu; Cristina Teodorescu; Monica Dan; Petre Capraru; Manuela Guran; Oana Istratescu; Alexandrina Tatu-Chitoiu; Aurelia Bumbu; Maria Dorobantu
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.